<DOC>
	<DOC>NCT00518297</DOC>
	<brief_summary>The purpose of this study is to to assess the effect of ATV 300 mg BID on the PK of raltegravir 400 mg BID, to assess the effect of raltegravir 400 mg BID on the PK of ATV 300 mg BID, and to assess the ECG effects of ATV 300 mg BID over 21 days, given with or without raltegravir 400 mg BID.</brief_summary>
	<brief_title>DDI HV (ATV - Merck)</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Healthy male and female subjects between the ages of 18 to 45 years old with a body mass index (BMI) of 18 to 32 kg/mÂ² Prior to enrollment, subjects must have physical and laboratory test findings within normal limits, and women of childbearing potential (WOCBP) must have a negative pregnancy test Any significant acute or chronic medical illness Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations. Use of any prescription drugs or overthecounter acid controllers within 4 weeks prior to study drug administration Use of any other drugs, including overthecounter medications and herbal preparations within 1 week prior to study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Antivirals / HIV</keyword>
</DOC>